Clinical Trial Detail

NCT ID NCT03685331
Title Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer
Recruitment Not yet recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Olaparib + Palbociclib

Age Groups: senior adult

Additional content available in CKB BOOST